CPIX
Cumberland Pharmaceuticals Inc.
CPIX offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over CPIX overall, supported by stronger fundamentals and lower modeled downside.
CPIX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
CPIX's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CPIX PE Valuation
CPIX has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CPIX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CPIX's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CPIX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.73 | -$0.51 |
| Q1 2026 | -$0.49 | -$0.24 |
| Q4 2025 | -$0.19 | +$0.28 |
| Q3 2025 | -$0.24 | +$0.53 |
| Q2 2025 | -$0.22 | +$0.51 |
| Q1 2025 | -$0.25 | +$0.34 |
| Q4 2024 | -$0.47 | -$0.03 |
| Q3 2024 | -$0.77 | -$0.60 |
CPIX lost $0.73 per share over the past year, a bigger loss than the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CPIX on earnings quality, reporting a profit while its opponent remains loss making.
CPIX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.8M | -19% |
| Q1 2026 | $9.1M | -22% |
| Q4 2025 | $13.7M | +31% |
| Q3 2025 | $8.3M | -8.7% |
| Q2 2025 | $10.8M | +10% |
| Q1 2025 | $11.7M | +38% |
| Q4 2024 | $10.4M | +12% |
| Q3 2024 | $9.1M | -9.9% |
CPIX's revenue is shrinking: $9M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -36% | -29 points |
| Q1 2026 | -34% | -45 points |
| Q4 2025 | -10% | +7.6 points |
| Q3 2025 | -24% | -5.1 points |
| Q2 2025 | -6.9% | +3.5 points |
| Q1 2025 | 11% | +33 points |
| Q4 2024 | -18% | +48 points |
| Q3 2024 | -19% | -0.1 points |
CPIX's operating margin was −36% last quarter, down 29 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CPIX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CPIX on profitability, with a higher operating margin.
CPIX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $130.5K | -84% |
| Q1 2026 | $387K | -90% |
| Q4 2025 | $3K | -100% |
| Q3 2025 | $163.4K | -64% |
| Q2 2025 | $817.3K | +$1.7M |
| Q1 2025 | $3.9M | +$6M |
| Q4 2024 | $1.9M | +92% |
| Q3 2024 | $460.1K | -61% |
CPIX still generates free cash flow, though less than at its 2023 peak: $683,899 over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CPIX on cash flow, with more consistent year-over-year improvement.
CPIX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +21.4K shares |
| 1 year | +0.1% | +21K shares |
| 3 years | +2.9% | +427K shares |
| 5 years | -0.8% | -128K shares |
| Available history | -2.5% | -386K shares |
CPIX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $61,001 |
| Q4 2025 | — |
| Q3 2025 | $10,439 |
| Q2 2025 | $7,171 |
| Q1 2025 | $245,868 |
| Q4 2024 | $98,383 |
| Q3 2024 | $98,815 |
CPIX has spent almost nothing on buybacks in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CPIX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -4.6x | Net Cash |
| Q3 2025 | -7.5x | Net Cash |
| Q2 2025 | -6.4x | Net Cash |
| Q1 2025 | -6.5x | Net Cash |
| Q2 2023 | -11.7x | Net Cash |
| Q4 2019 | -12.4x | Net Cash |
CPIX has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CPIX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.4 | Neutral |
| Stochastic | 26.9 | Neutral |
CPIX's weekly RSI is 51 (neutral) and its Stochastic is 27 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CPIX PE vs Healthcare Sector
CPIX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CPIX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.78 | 2.2% below |
| 20 week MA | $6.94 | 4.5% below |
| 50 week MA | $5.33 | 24% above |
| 100 week MA | $4.51 | 47% above |
| 200 week MA | $3.12 | 113% above |
CPIX has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 113% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CPIX on trend strength, trading above more of its moving averages.
CPIX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.14 | $3.06 | -40% |
| 2021 | $3.06 | $5.12 | +67% |
| 2022 | $5.12 | $2.11 | -59% |
| 2023 | $2.11 | $1.79 | -15% |
| 2024 | $1.79 | $2.32 | +30% |
| 2025 | $2.32 | $4.12 | +78% |
| 2026 YTD | $4.12 | $6.63 | +61% |
CPIX is up 61% so far in 2026, after finishing lower in three of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CPIX on returns for 2026, with the stronger performance.